The radiopharmaceutical preclinical CRO market reached USD 2.50 billion in 2026. The growth is driven by the demand for outsourced research services to evaluate radiopharmaceutical candidates before clinical advancement. These trends were analyzed by Deepa Pandey, Research Analyst, to curate this report. The industry-driven move toward targeted radioligand therapies (RLTs) and theranostic drug design has made mandatory nonclinical validation a core requirement for this specialized contract research sector. The report covers R&D and services, including molecular imaging, quantitative autoradiography, in vitro screening, and biodistribution.